Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986, and is headquartered in South Melbourne, Australia.